- 作者：Christine E. Richter ; Emiliano Cocco ; Stefania Bellone ; Dan-Arin Silasi ; Dominik Rü ; ttinger ; Masoud Azodi ; Peter E. Schwartz ; Thomas J. Rutherford ; Sergio Pecorelli ; Aless ; ro D. Santin
- 关键词：adecatumumab ; chemotherapy ; cytotoxicity ; EpCAM ; monoclonal antibody ; MT201 ; natural killer cell
- 刊名：American Journal of Obstetrics and Gynecology
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：203
- 期：6
- 页码：582.e1-582.e7
- 全文大小：641 K
Objective
We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human-monoclonal-antibody that targets EpCAM against chemotherapy-resistant ovarian disease.Study Design
EpCAM expression was evaluated by real-time polymerase chain reaction and flow cytometry. Sensitivity to MT201 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 4-hour chromium-release assays. The effect of interleukin-2 on MT201 ADCC was also studied.
Results
High messenger RNA expression by real-time polymerase chain reaction and high EpCAM surface expression by flow cytometry was detected in 71 % of ovarian cancers (5 of 7 cell lines). Although these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer-dependent cytotoxicity in vitro (range of killing, 0–7 % ), EpCAM-positive cell lines showed high sensitivity to MT201 ADCC (range of killing, 27–66 % ). Incubation with interleukin-2 further increased the cytotoxic activity against EpCAM-positive ovarian cancer cell lines.
Conclusion
MT201 may represent a novel, potentially highly effective treatment option for patients with ovarian carcinoma whose body is harboring disease refractory to chemotherapy.